Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.
1 report, 1 independent
Updated 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nektar Therapeutics
American healthcare company
Nothing else this week.
-
Leerink partners
U.S. investment bank
Related events
- Multiple financial firms, including KBC Group NV, WINTON GROUP Ltd, and Deutsche Bank, increased their stakes in Nektar Therapeutics on September 12, 2026.
- Leerink Partners started coverage on Nautilus Biotechnology on October 6, 2026.
- Market factors drive comparative business analysis between Nektar Therapeutics and Janux Therapeutics.
- Nathan Miller is associated with an investigation involving Nektar Therapeutics.
- Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.